Displaying 1901 - 1920 of 2211
Watson Pharmaceuticals, Inc. and Andrx Corporation., In the Matter of
A consent order settled charges that Watson Pharmaceuticals, Inc.’s proposed $1.9 billion acquisition of Andrx Corporation, would have likely led to competitive problems in the markets for 13 generic drug products. Watson was required to end its marketing agreements with Interpham Holdings, divest Andrx’s right to develop, make, and market generic extended release tablets that correct the effects of type 2 diabetes, and divest Andrx’s rights and assets related to the developing and marketing of 11 generic oral contraceptives.
There is a related federal proceeding and two related administrative proceedings:
FTC Charges Real Estate Groups with Anticompetitive Conduct in Limiting Consumers' Choice in Real Estate Services
FTC Finds Rambus Unlawfully Obtained Monopoly Power
Competition Policy and the Real Estate Industry: A Public Workshop hosted by the Federal Trade Commission and Department of Justice
FTC Resolves Aloha Petroleum Litigation
Dual Consent Orders Resolve Competitive Concerns About Chevrons $18 Billion Purchase of Unocal, FTCs 2003 Complaint Against Unocal
FTC Seeks Court Order to Force Blockbuster to Comply with Premerger Rules
Town Meetings on Patent System Reform
Oil Industry Merger Effects
Protecting Competition, FTC Clears Genzyme Corp.'s $1 Billion Acquisition of Ilex Oncology, Inc.
Peer-to-Peer File-Sharing Technology: Consumer Protection and Competition Issues
Displaying 1901 - 1920 of 2211